Tags

Type your tag names separated by a space and hit enter

PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Eur Urol. 2008 Mar; 53(3):547-53.EU

Abstract

OBJECTIVES

To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free survival after high-intensity focussed ultrasound (HIFU) therapy for localised prostate cancer as defined by the new ASTRO criteria.

METHODS

One hundred three patients after HIFU treatment (Ablatherm, EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively. Patients attended regular follow-up visits every 3 mo. Treatment failure was defined by the revised ASTRO criteria (PSA >or=2 ng/ml above nadir PSA, positive biopsy, if salvage treatment was administered). Patients were divided into three PSA nadir subgroups (group 1, <or=0.2 ng/ml; group 2, 0.21-1 ng/ml; group 3, >1 ng/ml). The disease-free survival rate (DFSR) was calculated by using life table methods. The log-rank test was used to compare the curves based on Kaplan-Meier models.

RESULTS

The median follow-up was 4.9 (3-8.6) yr. Mean time to PSA nadir was 6.4+/-5.1 mo. A PSA nadir of <or=0.2 ng/ml, 0.21-1 ng/ml, and >1ng/ml was reached by 64%, 22.3%, and 13.6% of patients, respectively. Treatment failure rates during follow-up were 4.5%, 30.4%, and 100%, respectively, for the three groups (p<0.001). The actuarial DFSRs at 5 yr were 95%, 55%, and 0%, respectively, for the 3 groups (p<0.001).

CONCLUSIONS

The PSA nadir after HIFU correlates highly significantly with treatment failure and DFSR, and can be applied in daily clinical practice. Promising oncological outcome is obtained if a PSA nadir of <or=0.2 ng/ml is reached.

Authors+Show Affiliations

Department of Urology, University of Regensburg, Krankenhaus St Josef, Regensburg, Germany. roman.ganzer@gmx.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

17662520

Citation

Ganzer, Roman, et al. "PSA Nadir Is a Significant Predictor of Treatment Failure After High-intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer." European Urology, vol. 53, no. 3, 2008, pp. 547-53.
Ganzer R, Rogenhofer S, Walter B, et al. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol. 2008;53(3):547-53.
Ganzer, R., Rogenhofer, S., Walter, B., Lunz, J. C., Schostak, M., Wieland, W. F., & Blana, A. (2008). PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. European Urology, 53(3), 547-53.
Ganzer R, et al. PSA Nadir Is a Significant Predictor of Treatment Failure After High-intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer. Eur Urol. 2008;53(3):547-53. PubMed PMID: 17662520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. AU - Ganzer,Roman, AU - Rogenhofer,Sebastian, AU - Walter,Bernhard, AU - Lunz,Jens-Claudio, AU - Schostak,Martin, AU - Wieland,Wolf F, AU - Blana,Andreas, Y1 - 2007/07/17/ PY - 2007/04/10/received PY - 2007/07/06/accepted PY - 2007/7/31/pubmed PY - 2008/5/14/medline PY - 2007/7/31/entrez SP - 547 EP - 53 JF - European urology JO - Eur Urol VL - 53 IS - 3 N2 - OBJECTIVES: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free survival after high-intensity focussed ultrasound (HIFU) therapy for localised prostate cancer as defined by the new ASTRO criteria. METHODS: One hundred three patients after HIFU treatment (Ablatherm, EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively. Patients attended regular follow-up visits every 3 mo. Treatment failure was defined by the revised ASTRO criteria (PSA >or=2 ng/ml above nadir PSA, positive biopsy, if salvage treatment was administered). Patients were divided into three PSA nadir subgroups (group 1, <or=0.2 ng/ml; group 2, 0.21-1 ng/ml; group 3, >1 ng/ml). The disease-free survival rate (DFSR) was calculated by using life table methods. The log-rank test was used to compare the curves based on Kaplan-Meier models. RESULTS: The median follow-up was 4.9 (3-8.6) yr. Mean time to PSA nadir was 6.4+/-5.1 mo. A PSA nadir of <or=0.2 ng/ml, 0.21-1 ng/ml, and >1ng/ml was reached by 64%, 22.3%, and 13.6% of patients, respectively. Treatment failure rates during follow-up were 4.5%, 30.4%, and 100%, respectively, for the three groups (p<0.001). The actuarial DFSRs at 5 yr were 95%, 55%, and 0%, respectively, for the 3 groups (p<0.001). CONCLUSIONS: The PSA nadir after HIFU correlates highly significantly with treatment failure and DFSR, and can be applied in daily clinical practice. Promising oncological outcome is obtained if a PSA nadir of <or=0.2 ng/ml is reached. SN - 0302-2838 UR - https://www.unboundmedicine.com/medline/citation/17662520/PSA_nadir_is_a_significant_predictor_of_treatment_failure_after_high_intensity_focussed_ultrasound__HIFU__treatment_of_localised_prostate_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(07)00916-5 DB - PRIME DP - Unbound Medicine ER -